{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:34:26Z","timestamp":1783060466012,"version":"3.54.6"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/jcp.0b013e31820f932a","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T08:21:14Z","timestamp":1298449274000},"page":"194-200","source":"Crossref","is-referenced-by-count":9,"title":["What Can We Learn From Chinese Randomized Controlled Trials? A Systematic Review and Meta-Analysis of Chinese Venlafaxine Studies"],"prefix":"10.1097","volume":"31","author":[{"given":"Markus","family":"Koesters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Dong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.respol.2005.08.006","article-title":"The emergence of China as a leading nation in science.","volume":"35","author":"Zhou","year":"2006","journal-title":"Res Policy"},{"key":"R3-10-20210128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(97)02419-7","article-title":"Language bias in randomised controlled trials published in English and German.","volume":"350","author":"Egger","year":"1997","journal-title":"Lancet"},{"key":"R4-10-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ije\/31.1.115","article-title":"Direction and impact of language bias in meta-analyses of controlled trials: empirical study.","volume":"31","author":"Juni","year":"2002","journal-title":"Int J Epidemiol"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(96)90538-3","article-title":"Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews.","volume":"347","author":"Moher","year":"1996","journal-title":"Lancet"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0197-2456(97)00150-5","article-title":"Do certain countries produce only positive results? A systematic review of controlled trials.","volume":"19","author":"Vickers","year":"1998","journal-title":"Control Clin Trials"},{"key":"R7-10-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr Bull"},{"key":"R8-10-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0895-4356(94)00172-M","article-title":"Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on meta-analysis.","volume":"48","author":"Cook","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"R9-10-20210128","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R11-10-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00213-007-0975-9","article-title":"Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.","volume":"196","author":"Weinmann","year":"2008","journal-title":"Psychopharmacology"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.","volume":"373","author":"Cipriani","year":"2009","journal-title":"The Lancet"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2007.06.027","article-title":"Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.","volume":"63","author":"Nemeroff","year":"2008","journal-title":"Biol Psychiatry"},{"key":"R14-10-20210128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00406-008-0849-0","article-title":"The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.","volume":"259","author":"Bauer","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R15-10-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1471-1842.2007.00734.x","article-title":"Five large Chinese biomedical bibliographic databases: accessibility and coverage.","volume":"25","author":"Xia","year":"2008","journal-title":"Health Info Libr J"},{"key":"R18-10-20210128","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"R21-10-20210128","first-page":"45","article-title":"A comparative study of venlafaxine and clomipramine in the treatment of depression.","volume":"23","author":"Chang","year":"2003","journal-title":"Clin Med"},{"key":"R22-10-20210128","first-page":"334","article-title":"Controlled study of venlafaxine and amitriptyline in the treatment of depression.","volume":"14","author":"Chen","year":"2002","journal-title":"Med J Chin Civil Adm"},{"key":"R23-10-20210128","first-page":"127","article-title":"A control study of venlafaxine and amitriptyline in senile depression.","volume":"11","author":"Du","year":"2005","journal-title":"J Clin Psychosom Dis"},{"key":"R24-10-20210128","first-page":"11","article-title":"A comparative study of venlafaxine and imipramine in the treatment of depression.","volume":"17","author":"Du","year":"2004","journal-title":"Shandong Arch Psychiatry"},{"key":"R25-10-20210128","first-page":"107","article-title":"A double-blind controlled study of venlafaxine and imipramine in patients with depressive disorder.","volume":"14","author":"Feng","year":"2001","journal-title":"Sichuan Mental Health"},{"key":"R26-10-20210128","first-page":"102","article-title":"A comparative study of venlafaxine and maprotiline in the treatment of senile depression.","volume":"13","author":"Li","year":"2005","journal-title":"Chin J Health Psychol"},{"key":"R27-10-20210128","first-page":"135","article-title":"A comparative study of venlafaxine and clomipramine in the treatment of depression.","volume":"19","author":"Liu","year":"2006","journal-title":"Shandong Arch Psychiatry"},{"key":"R28-10-20210128","first-page":"35","article-title":"A multicenter, double-blind, comparative study of venlafaxine and amitriptyline in the treatment of depression.","volume":"24","author":"Lu","year":"1998","journal-title":"Chin J Nerv Mental Dis"},{"key":"R29-10-20210128","first-page":"188","article-title":"A study on the efficacy of venlafaxine in treatment of senile depression in comparison with amitriptyline.","volume":"8","author":"Lu","year":"1999","journal-title":"Chin J N Drugs"},{"key":"R30-10-20210128","first-page":"74","article-title":"170 cases of venlafaxine in the treatment of depression.","volume":"17","author":"Lu","year":"2008","journal-title":"Chin J Clin Med Res"},{"key":"R31-10-20210128","first-page":"105","article-title":"A controlled study in the treatment of depression with venlafaxine extended release.","volume":"11","author":"Ou","year":"2001","journal-title":"J Clin Psychol Med"},{"key":"R32-10-20210128","first-page":"519","article-title":"The efficacy and tolerability of venlafaxine and fluoxetine in the treatment of patients with first-episode depression.","volume":"18","author":"Qin","year":"2006","journal-title":"Med J Chin Peoples Health"},{"key":"R33-10-20210128","first-page":"225","article-title":"A comparative study of venlafaxine and amitriptyline in the treatment of depression.","volume":"16","author":"Qu","year":"2004","journal-title":"Med J Chin Peoples Health"},{"key":"R34-10-20210128","first-page":"176","article-title":"A comparative study of venlafaxine and amitriptyline in the treatment of depression.","volume":"11","author":"Song","year":"2001","journal-title":"J Clin Psychol Med"},{"key":"R35-10-20210128","first-page":"112","article-title":"A comparative study of depression treatment effects with venlafaxine and amitriptyline.","volume":"11","author":"Song","year":"2003","journal-title":"Health Psychol J"},{"key":"R36-10-20210128","first-page":"617","article-title":"A comparative clinical study for venlafaxine versus fluoxetine in the treatment of depression.","volume":"14","author":"Sun","year":"2005","journal-title":"Chin J N Drugs"},{"key":"R37-10-20210128","first-page":"56","article-title":"Comparisons of the efficacy and tolerability of escitalopram and extended-release venlafaxine in the treatment of depression.","volume":"19","author":"Sun","year":"2010","journal-title":"Chin Pharm"},{"key":"R38-10-20210128","first-page":"517","article-title":"A double-blind comparison of venlafaxine (made in China) and doxepinnum for major depression and melancholia.","volume":"15","author":"Wang","year":"2003","journal-title":"Med J Chin Peoples Health"},{"key":"R39-10-20210128","first-page":"352","article-title":"The controlled study on venlafaxine and fluoxetine in depression.","volume":"6","author":"Wei","year":"2006","journal-title":"Nerv Dis Mental Health"},{"key":"R40-10-20210128","first-page":"727","article-title":"Comparision of venlafaxine vs maprotiline in the treatment of 83 patients with depression.","volume":"11","author":"Xu","year":"2002","journal-title":"Chin J N Drugs"},{"key":"R41-10-20210128","first-page":"8","article-title":"A doube-blind comparison of venlafaxine and amitriptyline in the treatment of depression.","volume":"31","author":"Zhang","year":"2000","journal-title":"Guangzhou Med J"},{"key":"R42-10-20210128","first-page":"132","article-title":"Comparison of venlafaxine with imipramine on post-stroke depression.","volume":"12","author":"Zhang","year":"2004","journal-title":"Health Psychol J"},{"key":"R43-10-20210128","first-page":"695","article-title":"A clinical control study of venlafaxine and fluoxetine in the treatment of depression patients.","volume":"2","author":"Zhang","year":"2004","journal-title":"Chin J Curr Clin Med"},{"key":"R44-10-20210128","first-page":"12","article-title":"Citalopram versus venlafaxine for the improvement of post-stroke depression.","volume":"9","author":"Zhao","year":"2005","journal-title":"Chin J Clin Rehabil"},{"key":"R45-10-20210128","first-page":"157","article-title":"The efficacy and tolerability of venlafaxine and fluoxetine in the treatment of elderly patients with first-episode depression.","volume":"38","author":"Zhou","year":"2005","journal-title":"Chin J Psychiatry"},{"key":"R46-10-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/JCP.0b013e3181e7784f","article-title":"Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a chinese population.","volume":"30","author":"Fang","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R47-10-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(99)00092-0","article-title":"Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.","volume":"58","author":"Anderson","year":"2000","journal-title":"J Affect Disord"},{"key":"R48-10-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1192\/bjp.180.5.396","article-title":"Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.","volume":"180","author":"Smith","year":"2002","journal-title":"Br J Psychiatry"},{"key":"R49-10-20210128","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/0269881108089821","article-title":"Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis.","volume":"23","author":"van den Broek","year":"2009","journal-title":"J Psychopharmacol (Oxf)"},{"key":"R50-10-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.yic.0000188214.46667.3f","article-title":"A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients.","volume":"21","author":"Ng","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"R51-10-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1745-6215-9-22","article-title":"An assessment of the quality of randomised controlled trials conducted in China.","volume":"9","author":"Zhang","year":"2008","journal-title":"Trials"},{"key":"R52-10-20210128","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cct.2008.05.003","article-title":"Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals.","volume":"29","author":"Xu","year":"2008","journal-title":"Contemp Clin Trials"},{"key":"R53-10-20210128","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdg203","article-title":"Citation indexes do not reflect methodological quality in lung cancer randomised trials.","volume":"14","author":"Berghmans","year":"2003","journal-title":"Ann Oncol"},{"key":"R55-10-20210128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2125.2006.02780.x","article-title":"Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study.","volume":"63","author":"Sim","year":"2007","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31820f932a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:59:13Z","timestamp":1620957553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201104000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31820f932a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}